Trial Profile
Certolizumab-Pegol in Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis :HUR-BIO (Hacettepe University Rheumatology Biologic Registry)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jul 2018
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Ankylosing spondylitis; Non-radiographic axial spondyloarthritis; Spondylarthritis
- Focus Therapeutic Use
- 17 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism